BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gao L, Hu Y, Shi X, Li X, Zhang D, Ren H. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. Ann Hepatol 2020;19:329-34. [PMID: 31884016 DOI: 10.1016/j.aohep.2019.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res 2022;52:337-51. [PMID: 35089634 DOI: 10.1111/hepr.13749] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Wang CR, Zhong GC, Chen ZW, Hu P. A Nomogram for Predicting Non-Rebound in HBV-Infected Pregnant Women With Mother-to-Child Transmission Prevention. Front Med (Lausanne) 2021;8:746759. [PMID: 34805216 DOI: 10.3389/fmed.2021.746759] [Reference Citation Analysis]